Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Goldstein, Barry J., Feinglos, Mark N., Lunceford, Jared K., Johnson, Jeremy, Williams-Herman, Debora E., for the Sitagliptin 036 Study Group·2007·Diabetes Care
DOI 10.2337/dc07-0627

Cited by (510)

Items 301–400 of 510

  1. Animal models to explore the effects of CNS drugs on food intake and energy expenditure
    Steve P. Vickers, Peter G. Clifton · 2012 · Neuropharmacology
  2. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy
    David Polidori, George A. Capuano, R. Qiu · 2015 · Diabetes Obesity and Metabolism
  3. Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions
    Kayo Fujita, Masayuki Kaneko, Mamoru Narukawa · 2016 · Clinical Drug Investigation
  4. Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
    Siew Hwa Ong, Matthias Blüher, Andy Schuetz · 2015 · ClinicoEconomics and Outcomes Research
  5. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
    Samuel S. Engel, Keaven M. Anderson, Hanson, Musliner, Helmut O. Steinberg · 2013 · Vascular Health and Risk Management
  6. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus
    Subodh Kumar · 2015 · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
  7. Combining the G ‐protein‐coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12‐week trial
    Xuejun Peng, JOHN F. MARCINAK, Marsha Gold Raanan, Charlie Cao · 2017 · Diabetes Obesity and Metabolism
  8. Beyond insulin replacement: addressing the additional needs of the diabetes patient
    GEORGE E. DAILEY · 2008 · Diabetes Obesity and Metabolism
  9. NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY
    Rithwick Rajagopal, Janet B. McGill · 2024 · Retina
  10. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Alan J. Garber · 2011 · PubMed
  11. Inertia on hypoglycemia: Highlight from a Taiwan subgroup analysis of Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
    Chih‐Yuan Wang, Ching‐Ling Lin, Tien-Shiang Huang, Ming-Nan Chien, Sheng‐Hwu Hsieh, Yu‐Yao Huang, Kuang‐Chung Shih, Shih‐Te Tu, Chwen‐Tzuei Chang, Chien‐Ning Huang et al. · 2012 · Diabetes Research and Clinical Practice
  12. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
    Jeffrey S. Freeman · 2010 · PubMed
  13. Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials
    George Grunberger · 2014 · European Journal of Clinical Pharmacology
  14. Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus
    Bhavik J. Pandya, Morgan Bron, Thérèse McCall, Andrew Peng Yu, Kristina S. Chen, Miles E. Mattson, Eric Qiong Wu · 2010 · Current Medical Research and Opinion
  15. Clinical review of sitagliptin: a DPP-4 inhibitor.
    Kamlesh Garg, C.D. Tripathi, Surinder Kumar · 2013 · PubMed
  16. Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss.
    Craig Spellman · 2008 · PubMed
  17. Incretin-based Therapy in Chronic Kidney Disease
    Nicole R. Pinelli, Carol L. Moore, Sarah Tomasello · 2010 · Advances in Chronic Kidney Disease
  18. Multidisciplinary Interventions
    Edward S. Horton, William T. Cefalu, Stuart T. Haines, Linda M. Siminerio · 2008 · The Science of Diabetes Self-Management and Care
  19. Is insulin the preferred treatment for HbA1c >9%?
    Zachary T. Bloomgarden · 2017 · Journal of Diabetes
  20. Explainable Prediction of Long-Term Glycated Hemoglobin Response Change in Finnish Patients with Type 2 Diabetes Following Drug Initiation Using Evidence-Based Machine Learning Approaches
    Gunjan Chandra, Piia Lavikainen, Pekka Siirtola, Satu Tamminen, Anusha Ihalapathirana, Tiina K. Laatikainen, Janne A. Martikainen, Juha Röning · 2025 · Clinical Epidemiology
  21. Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
    Won Jun Kim, Cheol‐Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun‐Jung Rhee, Won‐Young Lee, Ki Won Oh, Sung Woo Park et al. · 2011 · Diabetes & Metabolism Journal
  22. Glycated Albumin (GA) is More Advantageous than Hemoglobin A1c for Evaluating the Efficacy of Sitagliptin in Achieving Glycemic Control in Patients with Type 2 Diabetes
    Kenji Shima, Machiko Komatsu, Yoshihiko Noma, Keiko Miya · 2014 · Internal Medicine
  23. Sitagliptin: Is It Effective in Routine Clinical Practice?
    Rita Mohan Dallumal, S. S. Chua, David Bin-Chia Wu, Shireene Ratna Vethakkan · 2015 · International Journal of Endocrinology
  24. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers
    Kensuke Fukui, Hiroyuki Kawahito, Noriyuki Wakana, Masakazu Kikai, Kensuke Terada, Keita Yamamoto, Daisuke Irie, Taku Kato, Sonoko Miyagawa, Hiroyuki Yamada · 2015 · Journal of the Renin-Angiotensin-Aldosterone System
  25. Combination Therapy with a Dipeptidyl peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus
    Koichi Hirao, Hajime Maeda, Shinichiro Shirabe, Ritsuko Yamamoto, Tetsuyuki Hirao, Setsuko Hirao, Mikio Yamauchi, Keiko Arai · 2012 · Japanese Clinical Medicine
  26. Emerging role of insulin with incretin therapies for management of type 2 diabetes
    Rupa Ahluwalia, Jiten P Vora · 2011 · Diabetes Therapy
  27. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis
    Weiyi Gao, Q. Wang, Sufang Yu · 2016 · Journal of Endocrinological Investigation
  28. The Management of Glycemic Control in Associated Disorders
    Muhammad Junaid Imran, Sumreen Begum, Abdul Hafeez Kandhro, Nazia Ahmed, Rashida Qasim · 2017 · INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR)
  29. Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review
    A. V. Sidorov · 2020 · Effective Pharmacotherapy
  30. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)
    George Grunberger · 2013 · Journal of Diabetes
  31. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis
    Shuyan Gu, Xiaoqian Hu, Lizheng Shi, Xuemei Zhen, Xueshan Sun, Minzhuo Huang, Yuxuan Gu, Hengjin Dong · 2022 · Journal of Clinical Medicine
  32. Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
    Rongping Chen, Jing Li, Danqi Chen, Weiheng Wen, Susu Zhang, Jitong Li, Yuting Ruan, Zhen Zhang, Jia Man Sun, Hong Chen · 2024 · Diabetes Metabolic Syndrome and Obesity
  33. Glimepiride Strongly Enhances the Glucose-Lowering Effect in Triple Oral Antidiabetes Therapy with Sitagliptin and Metformin for Japanese Patients with Type 2 Diabetes Mellitus
    Keiko Arai, Hajime Maeda, Sin-ichiro Sirabe, Ritsuko Yamamoto, Mikio Yamauchi, Tetsuyuki Hirao, Setsuko Hirao, Koichi Hirao · 2013 · Diabetes Technology & Therapeutics
  34. Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors
    Susan A. Cornell · 2014 · Journal of Diabetes & Metabolism
  35. Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
    Thomas Blevins · 2010 · Postgraduate Medicine
  36. Observational Study on Dipeptidyl Peptidase-4 Inhibitors: A Real-Life Analysis on 360 Patients from the ASL VCO Territory in Italy
    G Saglietti, Giuseppe Placentino, Antonella Schellino · 2014 · Clinical Drug Investigation
  37. Diabetes
    Syed Khalid Imam · 2014 · Elsevier eBooks
  38. Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin
    Maryam Jameshorani, Saba Sayari, Narjes Kiahashemi, Nima Motamed · 2017 · Open Access Macedonian Journal of Medical Sciences
  39. Efficacy and safety of initial combination of DPP‐IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials
    Weiyi Gao, Jianjun Dong, J. Liu, Y. Li, Fupeng Liu, Long-Shan Yang, Xinli Zhou, Lin Liao · 2013 · Diabetes Obesity and Metabolism
  40. Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
    Jon Reynolds · 2009 · Diabetes Metabolic Syndrome and Obesity
  41. Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
    Stanley S. Schwartz · 2014 · Postgraduate Medicine
  42. Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
    Jennifer Green, Karen Karen, Mary Elizabeth Cox · 2010 · Diabetes Metabolic Syndrome and Obesity
  43. Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
    Wei-Tse Hung, Yuan-Jung Chen, Chun-Yu Cheng, Bruce I Ovbiagele, Meng Lee, Chia‐Yu Hsu · 2022 · Diabetes Research and Clinical Practice
  44. Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin
    Hye Soo Chung, Sunghwan Suh, Mi Yeon Kim, Soo Kyoung Kim, Hee Kyung Kim, Ji In Lee, Kyu Yeon Hur, Jae Hyeon Kim, Yong‐Ki Min, M.‐K. Lee et al. · 2013 · Journal of Diabetes Investigation
  45. Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
    Abdulrahman Alanazi · 2014 · Saudi Pharmaceutical Journal
  46. Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis
    Syed Shahzad Hasan, Qasim Aslam, Imarah Islam, Chia Siang Kow, Zaheer Babar · 2022 · Primary care diabetes
  47. Successful Long-Term Use of Sitagliptin for the Treatment of New-Onset Diabetes Mellitus After Solid Organ Transplantation: A Case Report
    Nicole R. Pinelli, Carrie W. Nemerovski, Todd M. Koelling · 2011 · Transplantation Proceedings
  48. Treating type 2 diabetes: incretin mimetics and enhancers
    Katherine E. Nori Janosz, Kerstyn C. Zalesin, Wendy M. Miller, Peter Andrew McCullough · 2009 · Therapeutic Advances in Cardiovascular Disease
  49. Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials
    Beibei Wu, Dongsheng Hong, Yao Xiao, Qingwei Zhao, Dongsheng Zheng · 2014 · Drug Design Development and Therapy
  50. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
    Angus Gill, Stephen P. Gray, Karin Agnes Maria Jandeleit-Dahm, Anna M.D. Watson · 2018 · Current Diabetes Reviews
  51. Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
    Tuan Dinh Le, Nga Thi Phi Nguyen, Son Tien Nguyen, Hoa Thi Thanh Tran, Lan Ho Thi Nguyen, Hoang Huy Duong, Ha Manh Nguyen, Binh Nhu Do · 2020 · Diabetes Metabolic Syndrome and Obesity
  52. [Metabolic syndrome and live kidney donor: is this syndrome a contraindication to donation?].
    Domingo Hernández, Alejandra Alvarez, A.A. Pérez de Armas, Margarita Rufino, Esteban Porrini, Armando Torres · 2009 · PubMed
  53. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes
    H. L. Katzeff, Debora Williams‐Herman, Lei Xu, Gregory T. Golm, H. Wang, Qingji Dong, J. RANDOLPH JOHNSON, Edward A. O’Neill, Keith D. Kaufman, Samuel S. Engel et al. · 2015 · Current Medical Research and Opinion
  54. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
    Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah, Sheldon W. Tobe · 2019 · Endocrinology Diabetes & Metabolism
  55. Sitagliptin — enhancing incretin action
    Ian W Campbell, Caroline Day · 2007 · The British Journal of Diabetes
  56. Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions
    Linling Que, Wei Qin, Yunfei Shi, Ying Ding, Kai Huang, Zhenzhong Qian, Bingjie Huang, Peipei Zhou, Qing He · 2023 · Frontiers in Pharmacology
  57. Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial
    Peter Uchenna Amadi, Justice Obinna Osuoha, Chidi N. Ekweogu, Suha Jarad, Esienanwan Esien Efiong, Prince C. Odika, C. C. Ejiofor, Oluchi Aloy-Amadi, Govind S. Gill, Chiamaka W. Adumekwe et al. · 2025 · Pharmacological Research
  58. Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes
    Deborah A. Hinnen · 2015 · The Science of Diabetes Self-Management and Care
  59. Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study
    Ping Shi, Xin Liu, Ting Li, Feifei Sun, Yan-Ping Liu, Shuqin Liu, Xiaomeng Gao, Yaping Ma, Yao Shi Fu, Yu Cao · 2021 · Drugs in R&D
  60. Importancia de la variabilidad del control glucémico diario en la consecución de los objetivos de control en la diabetes mellitus tipo 2: papel de los inhibidores de la dipeptidil peptidasa 4
    Francisco Javier Ampudia‐Blasco, Antonio Ceriello · 2010 · Medicina Clínica
  61. Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?
    Thaddeus John Bell, Eugene E. Wright · 2010 · Journal of the National Medical Association
  62. Trypsin-Treated β-Lactoglobulin Improves Glucose Tolerance in C57BL/6 Mice by Enhancing AMPK Activation and Glucose Uptake in Hepatocytes
    Yuichi Tsuda, Kaori Iwasawa, Minehiko Yokoyama, Makoto Yamaguchi · 2017 · Biological and Pharmaceutical Bulletin
  63. Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
    Ji Hyun Kim · 2015 · Diabetes & Metabolism Journal
  64. Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis
    Lingyu He, Shu Liu, Chun Shan, Yingmei Tu, Zhengqing Li, Xiaohua Douglas Zhang · 2016 · BMC Pharmacology and Toxicology
  65. Special Features: Incretin-based therapies in type 2 diabetes mellitus
    Chia Cw, Egan Jm, Chee W. Chia, Josephine Mary Egan, Address correspondence, Josephine M. Egan · 2014
  66. Targeting the Incretin System in Type 2 Diabetes Mellitus
    Matthew V. Potenza, Elliot J. Rayfield · 2009 · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
  67. Effects of a fixed-dose combination of sitagliptin and metformin versus respective monotherapies in newly diagnosed type 2 diabetic subjects
    Deepak Sadashiv Bhosle, Abhijeet Bhagat, Anant D. Patil, Jyoti Bobde, Amrapali A. Bhagat · 2015 · International Journal of Diabetes in Developing Countries
  68. Comparative study of efficacy and safety of sitagliptin versus glimepiride in patients of type-2 diabetes mellitus inadequately controlled with metformin alone
    Manuj Sharma, Rakesh Sonawane, Jozef Marko · 2016 · International Journal of Advances in Medicine
  69. Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance
    Sarah L Craig, Victor A. Gault, Gerd Hamscher, Nigel Irwin · 2020 · Journal of Endocrinology
  70. Sitagliptin and metformin – novel combination therapy
    Berhane Seyoum · 2011 · Expert Opinion on Pharmacotherapy
  71. Cost utility analysis of fixed-dose and free-dose combinations of oral medications in type 2 diabetes patients
    Varun Vaidya, Vamshi Ruthwik Anupindi, Sharrel Pinto, Megan A. Kaun · 2016 · Journal of Pharmaceutical Health Services Research
  72. Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration
    Carlos Cárceles Rodríguez, Emilio Fernández-Varón, Tamara Martin‐Giménez, Carla N. Aguirre Pascasio, Alexandra Arion, M. J. Rodríguez, Ignacio Ayala · 2018 · Journal of Equine Veterinary Science
  73. Efficacy and safety of sitagliptin as a third therapeutic agent in the treatment of type 2 diabetes mellitus
    Fatemeh Hayati, Amjad Hazim Al-Naemi, Teguh Haryo Sasongko, Gan Siew Hua, Wan Mohd Izani Wan Mohamed, Juhaida Daud, Nik Soriani Yaacob, Wan Mohamad Wan Bebakar · 2014 · journal of Diabetes Research and Clinical Metabolism
  74. Current developments in the treatment of diabetes: the incretin therapies
    David L Russell-Jones · 2010 · The British Journal of Diabetes
  75. Nodular panniculitis in a female toy poodle.
    K Post · 1983 · PubMed
  76. Molecular design of peptide therapeutics via N-terminal modification
    Damla Sürmeli, Tristan C. Dinsmore, Haley M. Anchukaitis, Vittorio Montanari, Martin Beinborn, Krishna Kumar · 2024 · Methods in enzymology on CD-ROM/Methods in enzymology
  77. A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors
    Tatjána Ábel · 2011 · InTech eBooks
  78. Nuevas terapias en diabetes: más allá de la insulina inyectable y de los antidiabéticos orales
    John Edwin Feliciano-Alfonso, Iván Darío Sierra Ariza · 2008 · Revista da Associação Médica Brasileira
  79. Metformin Based Dual-Combination Therapies in Drug Naïve Type 2 Diabetic Patients
    Dong‐Lim Kim · 2013 · Diabetes & Metabolism Journal
  80. Sitagliptin: an oral agent for glucose control
    Joan K. Bardsley, Robert E. Ratner · 2008 · Expert Review of Endocrinology & Metabolism
  81. Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Kathryn Johnson, Kathleen Schurr · 2011 · Clinical Medicine Insights Therapeutics
  82. Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
    Pornanong Aramwit, Bancha Satirapoj · 2013 · InTech eBooks
  83. In Silico Prediction of Potential Drug Combinations for Type 2 Diabetes Mellitus by an Integrated Network and Transcriptome Analysis
    Dan Teng, Yuning Gong, Zengrui Wu, Weihua Li, Yun Tang, Guixia Liu · 2021 · ChemMedChem
  84. Dapagliflozin combination therapy in type 2 diabetes mellitus
    Tamer G. Yacoub · 2015 · Postgraduate Medicine
  85. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin
    Juan José Gagliardino, Silvina Santoro, Sara Arellano, Guillermo Di Girolamo · 2008 · Expert Opinion on Pharmacotherapy
  86. Novel Approaches to the Treatment of Type 2 Diabetes
    Erin St. Onge, Shannon A. Miller, James R. Taylor · 2009 · Journal of Pharmacy Practice
  87. Insurance barriers and inequalities in health care access: evidence from dual practice
    Eva Goetjes, Katharina Elisabeth Blankart · 2024 · Health Economics Review
  88. Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Ammar ElTahir Ahmed, Zi Tan, Waddah Abd El-Radi, Krishnakumar K. Rajamani · 2025 · Cureus
  89. Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin
    Ashok K. Das, Pramod Gandhi, Banshi Saboo, Sanjay C Reddy, Rajeev Chawla, Abdul Hamid Zargar, RAJIV R. KOVIL, Manoj S Chawla, SK Sharma, Sunil Gupta et al. · 2021 · Journal of Family Medicine and Primary Care
  90. The Role of Incretins in Insulin Secretion
    Brock E. Schroeder, Orville Kolterman · 2009 · Springer eBooks
  91. Treatment options for type 2 diabetes:introducing the incretin‐based therapies
    A H Barnett · 2009 · Practical Diabetes
  92. Comparison of DPP-4 Inhibitors
    Nam Hoon Kim, Sin Gon Kim · 2013 · Journal of Korean Diabetes
  93. Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes
    Amir Hanna, Vincent C. Woo, Jean‐François Yale, Elaine M. Cooke · 2012 · Canadian Journal of Diabetes
  94. Practical strategies to normalize hyperglycemia without undue hypoglycemia in type 2 diabetes mellitus
    Christopher T. Kodl, Elizabeth R. Seaquist · 2008 · Current Diabetes Reports
  95. Efficacy and safety of Vildagliptin in the management of type 2 Diabetes Mellitus
    H Iftekar, Kalaiselvan, N S Gyanendra · 2012 · Indian Journal of Pharmacy Practice
  96. Glucagon-like peptide-1 and diabetes treatment
    Tina Vilsbøll, Kristine Juul Hare, Bagger, J.O, Filip Krag Knop · 2009 · Research at the University of Copenhagen (University of Copenhagen)
  97. Clinical effectiveness and cost‐effectiveness of first‐line early combination of dipeptidyl peptidase 4 inhibitors and metformin in patients with type 2 diabetes in Taiwan: A modelling study
    Thi Thuy Dung Nguyen, Hsuan‐Ming Chen, Hung‐Wei Lin, Huang‐Tz Ou, Chih‐Yuan Wang · 2025 · Diabetes Obesity and Metabolism
  98. Patterns and Clinical Outcomes of Sitagliptin/Metformin Extended-Release in Internal Medicine: A Real-World Multicenter Italian Study
    Mariarosaria De Luca, Michele Arcopinto, Giosiana Bosco, Sebastiano Cicco, Francesco Di Giacomo Barbagallo, Chiara Giacinti, Marialuisa Sveva Marozzi, Maristella Salvatora Masala, Miriam Pinna, Giacomo Pucci et al. · 2026 · Journal of Clinical Medicine
  99. Metformin: Historical Origins, Mechanisms of Action, and Emerging Clinical Applications
    Ye Hu, Xinmiao Zhang, Changwei Yang, Xiaohong Wu, Xiao Ye, J K Yu, Yunbei Yang · 2026 · Diabetes/Metabolism Research and Reviews
  100. Treatment Approaches and Challenges
    Ramin Malboosbaf, Neda Hatami · 2023 · BENTHAM SCIENCE PUBLISHERS eBooks